145 related articles for article (PubMed ID: 26056958)
1. Pulsed levosimendan therapy in the management of chronic end stage cardiac failure in 'adult congenital heart disease'.
Rafiq I; Freeman LJ
Int J Cardiol; 2015 Sep; 195():283-4. PubMed ID: 26056958
[No Abstract] [Full Text] [Related]
2. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
[TBL] [Abstract][Full Text] [Related]
3. First Experience With Levosimendan Therapy After Correction of Congenital Heart Disease.
Giordano R; Cantinotti M; Mannacio VA; Palma G
J Cardiothorac Vasc Anesth; 2017 Feb; 31(1):e19-e21. PubMed ID: 28277244
[No Abstract] [Full Text] [Related]
4. Inotropic agents in advanced heart failure: repetita iuvant?
De Luca L
Int J Cardiol; 2014 Sep; 176(1):6-7. PubMed ID: 25065330
[No Abstract] [Full Text] [Related]
5. The vasoactive-inotropic score and levosimendan: time for LVIS?
Favia I; Vitale V; Ricci Z
J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):e15-6. PubMed ID: 23507021
[No Abstract] [Full Text] [Related]
6. Peripartum cardiomyopathy: a new successful setting for levosimendan.
Benezet-Mazuecos J; de la Hera J
Int J Cardiol; 2008 Jan; 123(3):346-7. PubMed ID: 17324479
[No Abstract] [Full Text] [Related]
7. Early levosimendan administration may improve outcome in patients with subarachnoid hemorrhage complicated by acute heart failure.
Papanikolaou J; Tsolaki V; Makris D; Zakynthinos E
Int J Cardiol; 2014 Oct; 176(3):1435-7. PubMed ID: 25147072
[No Abstract] [Full Text] [Related]
8. Assessment of quality of life using three activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period.
Papadopoulou EF; Mavrogeni SI; Dritsas A; Cokkinos DV
Hellenic J Cardiol; 2009; 50(4):269-74. PubMed ID: 19622496
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial.
Ricci Z; Garisto C; Favia I; Vitale V; Di Chiara L; Cogo PE
Intensive Care Med; 2012 Jul; 38(7):1198-204. PubMed ID: 22527079
[TBL] [Abstract][Full Text] [Related]
11. Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
Mansiroglu AK; Oner E; Erturk M; Karakurt H; Somuncu MU; Birant A; Kalkan AK; Ozturk D; Eksik A
Acta Cardiol; 2016 Aug; 71(4):411-5. PubMed ID: 27594356
[No Abstract] [Full Text] [Related]
12. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure.
Caimmi PP; Grossini E; Molinari C; Vacca G; Teodori G
Ann Thorac Surg; 2006 Nov; 82(5):e33-4. PubMed ID: 17062205
[TBL] [Abstract][Full Text] [Related]
13. Management of acute cardiac failure by intracoronary administration of levosimendan.
Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
[TBL] [Abstract][Full Text] [Related]
14. Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure.
Spargias KS; Anifantakis A; Papadakis M; Iakovis P; Chatzigeorgiou G; Koutsogiannis N; Karatasakis G; Athanassopoulos G; Manginas A; Maounis T; Cokkinos DV
Ital Heart J; 2003 May; 4 Suppl 2():45S-49S. PubMed ID: 14635370
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
Jia Z; Guo M; Zhang YQ; Liang HQ; Zhang LY; Song Y
Cardiology; 2014; 128(2):195-201. PubMed ID: 24751462
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan. A promising future drug for refractory cardiac failure in children?
Kushwah S; Kumar A; Sahana KS
Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S57-60. PubMed ID: 27056655
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
Mebazaa A; Erhardt L
Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
Sargento L; Brito D; Matias JS; Madeira H
Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
[TBL] [Abstract][Full Text] [Related]
19. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH
Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737
[TBL] [Abstract][Full Text] [Related]
20. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
Silvetti S; Nieminen MS
Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
